OneDigital Investment Advisors LLC Makes New $400,000 Investment in TransMedics Group, Inc. $TMDX

Posted by Stanley Muller on Aug 20th, 2026

OneDigital Investment Advisors LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,020 shares of the company’s stock, valued at approximately $400,000.

Other large investors have also recently modified their holdings of the company. Flputnam Investment Management Co. purchased a new position in shares of TransMedics Group during the second quarter worth about $77,000. Global Retirement Partners LLC bought a new position in shares of TransMedics Group in the second quarter worth approximately $450,000. Bank of New York Mellon Corp purchased a new stake in TransMedics Group in the second quarter valued at approximately $12,869,000. State of Wyoming purchased a new stake in TransMedics Group in the second quarter valued at approximately $31,000. Finally, 180 Wealth Advisors LLC bought a new stake in TransMedics Group during the second quarter valued at approximately $276,000. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

TransMedics Group Stock Up 3.6%

Shares of NASDAQ TMDX opened at $93.97 on Thursday. The stock has a market capitalization of $3.25 billion, a P/E ratio of 24.16 and a beta of 1.90. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The firm’s 50 day simple moving average is $76.71 and its two-hundred day simple moving average is $95.63. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The company’s revenue was up 20.7% compared to the same quarter last year. As a group, analysts expect that TransMedics Group, Inc. will post 1.47 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on TMDX. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Stifel Nicolaus upped their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Finally, Weiss Ratings cut TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $124.18.

Get Our Latest Report on TransMedics Group

About TransMedics Group

(Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.